Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL6068478

LAZERTINIB MESYLATE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1.CS(=O)(=O)O.O
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL6068478
Name LAZERTINIB MESYLATE
Phase Approved
Structure Type MOL
InChI Key ZJPNGZUERUYZEG-UHFFFAOYSA-N
Therapeutic ✓ Yes
Parent Compound CHEMBL4558324
Active Moiety CHEMBL4558324

Known Names

JNJ-73841937-ZCY Lazcluze Lazertinib mesilate hydrate Lazertinib mesylate Lazertinib mesylate monohydrate Leclaza R-605024 R605024 YH25448AM
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
9
Known Names
2
Indications
2
Mechanisms

Molecular Properties

554.7
MW (Da)
4.10
ALogP
10
HBA
2
HBD
109.7
PSA (Ų)
0.28
QED
1
Ro5 Violations
10
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2024
Availability Prescription
Chirality Achiral

Routes of Administration

Oral
USAN Stem -tinib
USAN Year 2024

Extended Properties

Molecular Formula C31H40N8O7S
MW 668.78
Aromatic Rings 4
Heavy Atoms 41
NP-Likeness -1.60

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Epidermal growth factor receptor erbB1 inhibitor INHIBITOR Epidermal growth factor receptor ✓ ✓
Epidermal growth factor receptor erbB1 inhibitor INHIBITOR Epidermal growth factor receptor ✓ ✓

Indications

Carcinoma, Non-Small-Cell Lung Neoplasms

Data from ChEMBL 36 via Core Engine